Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Vanguard International High Dividend Yield ETF trades at $100.85. The key difference: Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | VYMI | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $30.81 | $101.60 |
52-Week Low | $16.87 | $79.76 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
VYMI trades at $100.57, up 0.8% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF offers international high-dividend exposure with a recent $1.26 dividend declared for June 2026. News coverage highlights its role in diversification and potential outperformance versus U.S. stocks over the next decade, backed by Vanguard's low 0.07% expense ratio and over 1,500 holdings.
Outlook is positive for income investors seeking global diversification and yield, with risks including currency fluctuations and regional economic volatility. Analyst sentiment favors VYMI for its sustainable dividends and valuation appeal relative to U.S. markets, though geopolitical tensions could pressure returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
